Toxic Hazards Research Unit annual technical report, 1969 Final report, Jun. 1968 - May 1969

Apollo materials toxicity screening tests and effects of ethylene glycol, monomethylhydrazine, NF3, OF2, and ClF

Measurements And Perceptions Of Writing Development: Omani Academic Writers In English

Using collaborative research methodology, this study reports on the writing development of a number of Omani teachers of English studying for a UK BA degree in Oman. It identifies the most useful criteria for measuring writing development, critiquing some previous measures. The measurements with the students' own perceptions of their development as writers were compared and the two ways of tracking writing development were evaluated. The discussion deals with some of the problems of interpreting data in the light of experience and background knowledge. It analyses some findings concerning the relationship between grammatical complexity and accuracy, and highlights the importance of affective factors in academic writing skills development

Liraglutide for the treatment of type 2 diabetes : a single technology appraisal

This paper presents a summary of the Evidence Review Group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The manufacturer proposed the use of liraglutide as a second or third drug in patients with type 2 diabetes whose glycaemic control was unsatisfactory with metformin, with or without a second oral glucoselowering drug. The submission included six manufacturer-sponsored trials that compared the efficacy of liraglutide against other glucose-lowering agents. Not all of the trials were relevant to the decision problem. The most relevant were Liraglutide Effects and Actions in Diabetes 5 (LEAD-5) (liraglutide used as part of triple therapy and compared against insulin glargine) and LEAD-6 [liraglutide in triple therapy compared against another glucagon like peptide-1 (GLP-1) agonist, exenatide]. Five of the six trials were published in full and one was then unpublished. Two doses of liraglutide, 1.2 and 1.8 mg, were used in some trials but in the two comparisons in triple therapy, against glargine and exenatide, only the 1.8-mg dose was used. Liraglutide in both doses was found to be clinically effective in lowering blood glucose concentration [glycated haemoglobin (HbA1c)], reducing weight (unlike other glucose-lowering agents, such as sulphonylureas, glitazones and insulins, which cause weight gain) and also reducing systolic blood pressure (SBP). Hypoglycaemia was uncommon. The ERG carried out meta-analyses comparing the 1.2- and 1.8-mg doses of liraglutide, which suggested that there was no difference in control of diabetes, and only a slight difference in weight loss, insufficient to justify the extra cost

Education and public social work

Thesis (M.S.)--Boston Universit

Method and means for providing an absolute power measurement capability Patent

Input radio frequency circuit for switching type absolute temperature measuring radiometer for noise source

Evidence review : liraglutide for the treatment of type 2 diabetes

This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process. The manufacturer proposed the use of liraglutide as a second or third drug in patients with type 2 diabetes whose glycaemic control was unsatisfactory with metformin, with or without a second oral glucose-lowering drug. The submission included six manufacturer-sponsored trials that compared the efficacy of liraglutide against other glucose-lowering agents. Not all of the trials were relevant to the decision problem. The most relevant were Liraglutide Effects and Actions in Diabetes 5 (LEAD-5) (liraglutide used as part of triple therapy and compared against insulin glargine) and LEAD-6 [liraglutide in triple therapy compared against another glucagon-like peptide-1 agonist, exenatide]. Five of the six trials were published in full and one was then unpublished. Two doses of liraglutide, 1.2 and 1.8 mg, were used in some trials, but in the two comparisons in triple therapy, against glargine and exenatide, only the 1.8-mg dose was used. Liraglutide in both doses was found to be clinically effective in lowering blood glucose concentration [glycated haemoglobin (HbA1c)], reducing weight (unlike other glucose-lowering agents, such as sulphonylureas, glitazones and insulins, which cause weight gain) and also reducing systolic blood pressure (SBP). Hypoglycaemia was uncommon. The ERG carried out meta-analyses comparing the 1.2- and 1.8-mg doses of liraglutide, which suggested that there was no difference in control of diabetes, and only a slight difference in weight loss, insufficient to justify the extra cost. The cost-effectiveness analysis was carried out using the Center for Outcomes Research model. The health benefit was reported as quality-adjusted life-years (QALYs). The manufacturer estimated the cost-effectiveness to be £15,130 per QALY for liraglutide 1.8 mg compared with glargine, £10,054 per QALY for liraglutide 1.8 mg compared with exenatide, £10,465 per QALY for liraglutide 1.8 mg compared with sitagliptin, and £9851 per QALY for liraglutide 1.2 mg compared with sitagliptin. The ERG conducted additional sensitivity analyses and concluded that the factors that carried most weight were: in the comparison with glargine, the direct utility effects of body mass index (BMI) changes and SBP, with some additional contribution from HbA1c in the comparison with exenatide, HbA1c, with some additional effects from cholesterol and triglycerides in the comparison with sitagliptin, HbA1c and direct utility effects of BMI changes. The European Medicines Agency has approved liraglutide in dual therapy with other oral glucose-lowering agents. NICE guidance recommends the use of liraglutide 1.2 mg in triple therapy when glycaemic control remains or becomes inadequate with a combination of two oral glucose-lowering drugs. The use of liraglutide 1.2 mg in a dual therapy is indicated only in patients who are intolerant of, or have contraindications to, three oral glucose-lowering drugs. The use of liraglutide 1.8 mg was not approved by NICE. The ERG recommends research into the (currently unlicensed) use of liraglutide in combination with long-acting insulin

Community orientations toward a protective agency

Thesis (M.S.)--Boston Universit

Trypanosome invasion of mammalian cells requires activation of the TGFβ signaling pathway

AbstractTrypanosoma cruzi invades most nucleated mammi lian cells by as yet unknown mechanisms. We repoi here that while T. cruzi attaches to epithelial cells lacl ing signaling transforming growth factor β (TGFβ) receptor I or II, the adherent parasites cannot penetrat and replicate inside the mutant cells, as they do i parental cells. Invasion of the mutants is restored by transfection with the TGFβ receptor genes, as are biological responses to TGFβ. Similar rescue of bot TGFβ antiproliferative response and T. cruzi invasio was demonstrated in a hybrid of TGFβ-resistant bladder and colon carcinoma cells. In addition, T. cruzi di not efficiently invade epithelial cells with dysfunctio of the intracellular signaling cascade caused by th constitutive expression of the cyclin-dependent kinas cdk4 or of the oncogene H-ras. Treatment with TGFβ, but not with other anti proliferative agents of nor phagocytic cells, greatly enhances T. cruzi invasior Moreover, infective, but not noninfective, trypanosome strongly induce a TGFβ-responsive reporter gene i TGFβ-sensitive, but not in TGFβ-insensitive, cell line: Thus, T. cruzi itself may directly trigger activation of the TGFβ signaling pathway required for parasite entr into the mammalian cells

Enhancing dietary specialization metrics in observational studies of wild animal populations

Studies of intraspecific dietary variation can greatly enrich our view of a species' niche and role in the ecosystem, particularly when species with broad diets are found to be composed of generalist and specialist individuals. However, the current framework for quantifying dietary specialization leaves certain standards unformalized and is susceptible to overestimating specialization when there are few repeated observations per individual, as is often the case in observational studies of wild populations. Here, we use the hihi (Notiomystis cincta), a threatened New Zealand passerine, as a case study for demonstrating how existing statistical tools can be applied to strengthen the dietary specialization framework. First, we assess whether the reliability of common dietary measures can be improved through Bayesian adjustments and by using rarefaction to compare uncertainty levels of metrics calculated from different sample sizes. As diet links closely to environmental factors, we also demonstrate how adding phenological data and habitat assessments to standard protocols can help validate our dietary measures as evidence for resource selection rather than random foraging. Finally, in light of our finding that diet predicts survival in hihi, we discuss the utility of dietary specialization for elucidating broader behavioral syndromes.Peer reviewe